Ahead of the FDA’s decision window, another report said UniQure’s timeline is now clear for an advisory committee review and a May 1 decision date for its Huntington’s gene therapy. The market focus remains on whether the agency will align with its Priority Review acceptance and how the company’s long-term dataset will be evaluated. The same update also referenced a separate regulatory catalyst in the sector, with Inovia’s stock rising after an approval event. For investors and clinicians, the core signal is the convergence of FDA procedural milestones—adcomm plus decision timing—around a lead candidate in a high-unmet-needs neurodegenerative space.